Director Cox Troy was granted 62,910 shares, increasing direct ownership by 39% to 224,730 units (SEC Form 4)

$LAB
Biotechnology: Laboratory Analytical Instruments
Industrials
Get the next $LAB alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $LAB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LAB

DatePrice TargetRatingAnalyst
2/27/2025Overweight → Sector Weight
KeyBanc Capital Markets
4/16/2024$3.50Buy
TD Cowen
4/4/2024$3.25Buy
Jefferies
7/12/2023$4.00Overweight
KeyBanc Capital Markets
More analyst ratings

$LAB
Press Releases

Fastest customizable press release news feed in the world

See more
  • Standard BioTools to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that company management will participate in the following investor conferences: TD Cowen's 45th Annual Healthcare Conference - March 3rd – 5th, 2025 Presenting on Monday, March 3, 2025, at 3:10 p.m. ET2025 Leerink Partners Global Healthcare Conference - March 9th – 12th, 2025Participating in investor meetings on March 12thKeyBanc's 5th Annual Healthcare Forum – March 18th & 19th, 2025Presenting on Wednesday, March 19, 2025, at 4:30 p.m. ET Presentations will be webcast live and available on the Investor Relations page of the Company's website at Events & Presentations. A rec

    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

    SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the fourth quarter and fiscal year ended December 31, 2024. Recent Highlights: Full Year 2024 pro forma combined revenue of $175.1 million17% Full Year reduction in pro forma operating loss and 33% year over year improvement in adjusted EBITDA Additional $10 million in operational cost reductions, now totaling $90 million in synergies over 12 monthsStrong Balance sheet with $295 million in cash, cash equivalents, restricted cash, short-term investments and no material debt at year end 2024 expected to provide suffi

    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025

    SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standar

    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$LAB
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$LAB
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$LAB
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$LAB
SEC Filings

See more

$LAB
Leadership Updates

Live Leadership Updates

See more
  • Standard BioTools Appoints Alex Kim as Chief Financial Officer

    SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools' finance organization. Michael Egholm, President and Chief Executive Officer of Standard BioTools, said, "I am thrilled to announce Alex as our next CFO. Having co-founded Standard BioTools with me, Alex's deep understan

    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

    Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

    $EXAS
    $ILMN
    $LAB
    $ME
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Standard BioTools Appoints Jeffrey Black as Chief Financial Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Industry veteran Jeffrey Black brings 30 years of financial and operating leadership experience Vikram Jog to become Special Advisor for transition period SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced the appointment of Jeffrey Black as Senior Vice President and Chief Financial Officer effective today. Black will lead Standard BioTools' finance, accounting and investor relations functions, reporting to Michael Egholm, Ph.D., President and Chief Executive Officer. Vikram Jog will remain at the company for a period as Special Advisor to th

    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$LAB
Financials

Live finance-specific insights

See more
  • Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

    SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the fourth quarter and fiscal year ended December 31, 2024. Recent Highlights: Full Year 2024 pro forma combined revenue of $175.1 million17% Full Year reduction in pro forma operating loss and 33% year over year improvement in adjusted EBITDA Additional $10 million in operational cost reductions, now totaling $90 million in synergies over 12 monthsStrong Balance sheet with $295 million in cash, cash equivalents, restricted cash, short-term investments and no material debt at year end 2024 expected to provide suffi

    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025

    SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standar

    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Standard BioTools Reports Third Quarter 2024 Financial Results

    SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company") today announced unaudited interim financial results for the third quarter ended September 30, 2024. Recent Highlights: Reported third quarter 2024 revenue of $45 million Ongoing merger cost synergy realization delivered 50% adjusted EBITDA improvement and 35% net loss improvement year-over-yearOperationalized approximately $80 million in merger synergies, expected to be fully realized in 2025, and reinforcing path to adjusted EBITDA break-even in 2026Balance sheet as of September 30, 2024, includes $368 million cash, cash equivalents, restricted cash and short-te

    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$LAB
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more